Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810544 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Tango Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 191
- Enrollment target
- 13
- Study locations
NCT06810544: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Tango Therapeutics.
NCT06810544 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 191 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06810544, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Tango Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 191 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Primary Outcome
To determine the MTD, recommended dose(s) (RD), and dosing schedule of TNG456 monotherapy and in combination with abemaciclib
Conditions Studied
Interventions
- DRUG TNG456
- DRUG abemaciclib
Study Locations (13)
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic Scottsdale - Scottsdale
California
- University of California, Irvine - Irvine
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Florida
- Mayo Clinic Jacksonville - Jacksonville
Illinois
- Northwestern Memorial Hospital - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
What NCT06810544 shows while recruiting
NCT06810544 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which TNG456 is the first listed.
NCT06810544 lists 13 locations in 12 states (New York, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06810544 about?
NCT06810544 is a clinical study titled "Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss". This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumo...
What is the current status of trial NCT06810544?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2025-03-24. Estimated completion is 2027-09-30.
What conditions does trial NCT06810544 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Solid Tumor, Brain Tumor, Glioma, Malignant.
What interventions are being tested in trial NCT06810544?
The interventions under investigation include: TNG456 (DRUG), abemaciclib (DRUG).
Who is sponsoring clinical trial NCT06810544?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810544 being conducted?
This trial has 13 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06810544's enrollment target sits among peer trials
191 170th of 454 higher than 284 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI